8221 results for "canc*"

in 13.56 milliseconds.

• Tumour sample for patient SA1035

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA1035

  Dataset EGAD00001009258

• Tumour sample for patient SA994

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA994

  Dataset EGAD00001009259

• Tumour sample for patient SA604

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA604

  Dataset EGAD00001009260

• Tumour sample for patient SA605

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA605

  Dataset EGAD00001009261

• Tumour sample for patient SA609

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA609

  Dataset EGAD00001009262

• Normal sample for patient SA596

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA596

  Dataset EGAD00001009245

• Widespread hypertranscription in aggressive human cancers

  Data used to validate RNAmp tool.

  Dataset EGAD00001009285

• NLG-LBC-05 ctDNA project sequencing data

  Low-pass whole-genome sequencing of pretherapy lymphoma cfDNA and targeted sequencing of cfDNA, tumor tissue and whole-blood samples of NLG-LBC-05 patient samples and cfDNA of nine subjects with no known cancer. Hybrid capture target enrichment; panel target and sequencing information provided in PMID:34932792. FASTQ files provided for targeted sequencing, separate sequencing runs per sample noted with prefix "run" if applicable. Sequences from DTX1 and KLHL6 targets are advised to be excluded from analyses due to PCR/plasmid contaminants of in-house origin.

  Dataset EGAD00001009337

• Clinical cancer panel sequencing (UCSF500) analysis of TERT promoter duplication in GBM.

  Dataset contains paired-end clinical cancer panel sequencing (UCSF500) data from 2 samples of an initial tumor and one sample of a recurrence from one GBM patient and one sample from a second GBM patient.

  Dataset EGAD00001009286

• WTS and WES of Renal Cell Carcinoma Tumors From a Phase III Anti-Angiogenic Adjuvant Therapy Trial

  Archival de-identified formalin-fixed paraffin-embedded RCC tumor tissue blocks from nephrectomy or tumor biopsy were processed as per below and the same sections were used for both DNA and RNA extractions. For WES (ACE version 3; Illumina NovaSeq), samples were profiled using Personalis ACE Cancer Exome (Personalis, Inc, Menlo Park, CA) Whole-transcriptome profiles were generated by RNA-seq (Accuracy and Content Enhanced (ACE) version 3; Illumina NovaSeq) using Personalis ACE Cancer Transcriptome (Personalis, Inc, Menlo Park, CA ) Of the 615 patients in the intent-to-treat population in S-TRAC trial, 193 individual specimens were available for molecular profiling, of which 171 (27.8%) (sunitinib, n = 91; placebo, n = 80) returned results for the WES analysis, and 133 (21.6%) (sunitinib, n = 72; placebo, n = 61) returned results for the GES analysis. Of the 138 WTS samples with data, replicates for two patients were summarized by median expression, and three samples were excluded from the final analysis due to low counts.

  Dataset EGAD00001009294